Latest Us Market News

4DMedical Limited has raised AU$150 million to accelerate the commercial rollout of its FDA-cleared CT, VQ lung imaging technology in the US, leveraging a strategic partnership with Philips. This funding aims to expand adoption across major medical centres and government healthcare programs.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

City Chic Collective reports a robust 71% rise in underlying EBITDA for the first half of FY26, powered by strong ANZ revenue growth and strategic inventory management in the US despite tariff headwinds.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

Vitasora Health has completed an A$11 million capital raise, including a cornerstone investment, bolstering its balance sheet to support ambitious growth in the US healthcare market. The company targets cash flow breakeven by the end of FY2026 amid expanding patient programs and new partnerships.

Black Bear Minerals has extended gold-silver mineralisation by 280 metres north along the Rebel Trend at its Independence Project in Nevada, signalling promising growth potential. The company plans a Mineral Resource update in Q2 2026, supported by strong funding and strategic acquisitions.

4DMedical Limited has raised $150 million through a well-supported institutional placement to accelerate the commercialisation of its innovative lung imaging product CT – VQ™ in the US market. The capital raise comes with minimal dilution and increased insider confidence.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.

Ragusa Minerals has addressed recent unusual trading activity, confirming no undisclosed information while advancing its acquisition of a controlling stake in Pegasus Tel Inc. and the Purple Pansy Project in Arizona.

Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.